Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8411 |
Intermediate Similarity |
NPD9605 |
Phase 3 |
0.8369 |
Intermediate Similarity |
NPD282 |
Approved |
0.8322 |
Intermediate Similarity |
NPD1119 |
Phase 2 |
0.8108 |
Intermediate Similarity |
NPD2253 |
Discontinued |
0.8079 |
Intermediate Similarity |
NPD7531 |
Clinical (unspecified phase) |
0.8067 |
Intermediate Similarity |
NPD249 |
Approved |
0.8067 |
Intermediate Similarity |
NPD250 |
Approved |
0.8028 |
Intermediate Similarity |
NPD1128 |
Approved |
0.8028 |
Intermediate Similarity |
NPD1127 |
Approved |
0.8014 |
Intermediate Similarity |
NPD281 |
Approved |
0.8014 |
Intermediate Similarity |
NPD252 |
Clinical (unspecified phase) |
0.7961 |
Intermediate Similarity |
NPD186 |
Discovery |
0.7961 |
Intermediate Similarity |
NPD195 |
Approved |
0.7919 |
Intermediate Similarity |
NPD1118 |
Discontinued |
0.7919 |
Intermediate Similarity |
NPD549 |
Approved |
0.7917 |
Intermediate Similarity |
NPD9632 |
Phase 3 |
0.7815 |
Intermediate Similarity |
NPD1117 |
Clinical (unspecified phase) |
0.7771 |
Intermediate Similarity |
NPD3107 |
Discontinued |
0.7771 |
Intermediate Similarity |
NPD1750 |
Clinical (unspecified phase) |
0.7771 |
Intermediate Similarity |
NPD1369 |
Phase 2 |
0.777 |
Intermediate Similarity |
NPD535 |
Approved |
0.7756 |
Intermediate Similarity |
NPD283 |
Approved |
0.7736 |
Intermediate Similarity |
NPD2646 |
Discontinued |
0.7736 |
Intermediate Similarity |
NPD2624 |
Phase 2 |
0.7703 |
Intermediate Similarity |
NPD194 |
Clinical (unspecified phase) |
0.7697 |
Intermediate Similarity |
NPD185 |
Approved |
0.7658 |
Intermediate Similarity |
NPD242 |
Approved |
0.7658 |
Intermediate Similarity |
NPD338 |
Approved |
0.7625 |
Intermediate Similarity |
NPD1732 |
Phase 3 |
0.761 |
Intermediate Similarity |
NPD339 |
Approved |
0.7597 |
Intermediate Similarity |
NPD166 |
Approved |
0.7595 |
Intermediate Similarity |
NPD536 |
Clinical (unspecified phase) |
0.7569 |
Intermediate Similarity |
NPD78 |
Approved |
0.7569 |
Intermediate Similarity |
NPD9544 |
Approved |
0.7566 |
Intermediate Similarity |
NPD193 |
Suspended |
0.7562 |
Intermediate Similarity |
NPD169 |
Phase 2 |
0.7468 |
Intermediate Similarity |
NPD582 |
Approved |
0.7405 |
Intermediate Similarity |
NPD548 |
Clinical (unspecified phase) |
0.7361 |
Intermediate Similarity |
NPD2221 |
Clinical (unspecified phase) |
0.7353 |
Intermediate Similarity |
NPD5666 |
Phase 2 |
0.7347 |
Intermediate Similarity |
NPD1775 |
Approved |
0.7347 |
Intermediate Similarity |
NPD1085 |
Approved |
0.7329 |
Intermediate Similarity |
NPD579 |
Clinical (unspecified phase) |
0.7305 |
Intermediate Similarity |
NPD1777 |
Approved |
0.7305 |
Intermediate Similarity |
NPD1776 |
Approved |
0.7301 |
Intermediate Similarity |
NPD217 |
Approved |
0.7301 |
Intermediate Similarity |
NPD219 |
Phase 3 |
0.7301 |
Intermediate Similarity |
NPD220 |
Clinical (unspecified phase) |
0.7301 |
Intermediate Similarity |
NPD216 |
Approved |
0.7301 |
Intermediate Similarity |
NPD218 |
Approved |
0.725 |
Intermediate Similarity |
NPD3085 |
Phase 1 |
0.7222 |
Intermediate Similarity |
NPD580 |
Discontinued |
0.7205 |
Intermediate Similarity |
NPD3086 |
Phase 3 |
0.7163 |
Intermediate Similarity |
NPD9358 |
Approved |
0.7163 |
Intermediate Similarity |
NPD9359 |
Approved |
0.716 |
Intermediate Similarity |
NPD2647 |
Phase 3 |
0.7153 |
Intermediate Similarity |
NPD578 |
Discontinued |
0.7126 |
Intermediate Similarity |
NPD3083 |
Approved |
0.7117 |
Intermediate Similarity |
NPD213 |
Clinical (unspecified phase) |
0.7117 |
Intermediate Similarity |
NPD214 |
Approved |
0.7103 |
Intermediate Similarity |
NPD9288 |
Approved |
0.7103 |
Intermediate Similarity |
NPD9292 |
Approved |
0.7103 |
Intermediate Similarity |
NPD76 |
Approved |
0.7103 |
Intermediate Similarity |
NPD9289 |
Approved |
0.7055 |
Intermediate Similarity |
NPD9290 |
Approved |
0.7048 |
Intermediate Similarity |
NPD4074 |
Clinical (unspecified phase) |
0.7034 |
Intermediate Similarity |
NPD9606 |
Approved |
0.7 |
Intermediate Similarity |
NPD7988 |
Suspended |
0.7 |
Intermediate Similarity |
NPD247 |
Clinical (unspecified phase) |
0.6986 |
Remote Similarity |
NPD9607 |
Approved |
0.6983 |
Remote Similarity |
NPD5683 |
Clinical (unspecified phase) |
0.6983 |
Remote Similarity |
NPD5684 |
Clinical (unspecified phase) |
0.6983 |
Remote Similarity |
NPD5682 |
Phase 3 |
0.6971 |
Remote Similarity |
NPD1412 |
Clinical (unspecified phase) |
0.6962 |
Remote Similarity |
NPD1430 |
Approved |
0.6962 |
Remote Similarity |
NPD1431 |
Approved |
0.6914 |
Remote Similarity |
NPD4171 |
Clinical (unspecified phase) |
0.6889 |
Remote Similarity |
NPD6417 |
Clinical (unspecified phase) |
0.6886 |
Remote Similarity |
NPD546 |
Clinical (unspecified phase) |
0.6863 |
Remote Similarity |
NPD248 |
Discontinued |
0.6846 |
Remote Similarity |
NPD4262 |
Discontinued |
0.6839 |
Remote Similarity |
NPD209 |
Clinical (unspecified phase) |
0.6829 |
Remote Similarity |
NPD3708 |
Phase 2 |
0.6798 |
Remote Similarity |
NPD4716 |
Approved |
0.6778 |
Remote Similarity |
NPD1692 |
Approved |
0.6774 |
Remote Similarity |
NPD545 |
Clinical (unspecified phase) |
0.6772 |
Remote Similarity |
NPD1808 |
Phase 1 |
0.676 |
Remote Similarity |
NPD4744 |
Clinical (unspecified phase) |
0.6732 |
Remote Similarity |
NPD870 |
Clinical (unspecified phase) |
0.6721 |
Remote Similarity |
NPD2630 |
Approved |
0.6721 |
Remote Similarity |
NPD2632 |
Approved |
0.6721 |
Remote Similarity |
NPD2631 |
Clinical (unspecified phase) |
0.6712 |
Remote Similarity |
NPD9374 |
Approved |
0.6712 |
Remote Similarity |
NPD9086 |
Approved |
0.6708 |
Remote Similarity |
NPD2179 |
Discontinued |
0.6705 |
Remote Similarity |
NPD3081 |
Clinical (unspecified phase) |
0.669 |
Remote Similarity |
NPD9373 |
Approved |
0.6667 |
Remote Similarity |
NPD547 |
Clinical (unspecified phase) |
0.6646 |
Remote Similarity |
NPD1120 |
Approved |
0.6646 |
Remote Similarity |
NPD1121 |
Approved |
0.6644 |
Remote Similarity |
NPD307 |
Approved |
0.657 |
Remote Similarity |
NPD516 |
Clinical (unspecified phase) |
0.6552 |
Remote Similarity |
NPD8955 |
Approved |
0.6552 |
Remote Similarity |
NPD8954 |
Approved |
0.6512 |
Remote Similarity |
NPD5321 |
Phase 3 |
0.6506 |
Remote Similarity |
NPD775 |
Approved |
0.6488 |
Remote Similarity |
NPD353 |
Discontinued |
0.6486 |
Remote Similarity |
NPD9406 |
Approved |
0.6486 |
Remote Similarity |
NPD7138 |
Phase 2 |
0.6407 |
Remote Similarity |
NPD4182 |
Phase 3 |
0.6407 |
Remote Similarity |
NPD4183 |
Phase 3 |
0.6391 |
Remote Similarity |
NPD7842 |
Phase 2 |
0.6376 |
Remote Similarity |
NPD9584 |
Phase 2 |
0.6369 |
Remote Similarity |
NPD9633 |
Phase 3 |
0.6358 |
Remote Similarity |
NPD9360 |
Approved |
0.6343 |
Remote Similarity |
NPD5768 |
Phase 2 |
0.633 |
Remote Similarity |
NPD4054 |
Clinical (unspecified phase) |
0.6325 |
Remote Similarity |
NPD7158 |
Phase 1 |
0.6301 |
Remote Similarity |
NPD2604 |
Approved |
0.6275 |
Remote Similarity |
NPD9409 |
Discontinued |
0.625 |
Remote Similarity |
NPD237 |
Clinical (unspecified phase) |
0.6244 |
Remote Similarity |
NPD2965 |
Clinical (unspecified phase) |
0.6221 |
Remote Similarity |
NPD1731 |
Clinical (unspecified phase) |
0.6212 |
Remote Similarity |
NPD2877 |
Clinical (unspecified phase) |
0.6212 |
Remote Similarity |
NPD2876 |
Phase 3 |
0.6207 |
Remote Similarity |
NPD3697 |
Discontinued |
0.6196 |
Remote Similarity |
NPD1046 |
Clinical (unspecified phase) |
0.619 |
Remote Similarity |
NPD2152 |
Clinical (unspecified phase) |
0.6185 |
Remote Similarity |
NPD2180 |
Approved |
0.6178 |
Remote Similarity |
NPD9408 |
Phase 3 |
0.6174 |
Remote Similarity |
NPD9375 |
Discontinued |
0.6163 |
Remote Similarity |
NPD231 |
Clinical (unspecified phase) |
0.6154 |
Remote Similarity |
NPD798 |
Discontinued |
0.615 |
Remote Similarity |
NPD2824 |
Phase 2 |
0.6122 |
Remote Similarity |
NPD1816 |
Clinical (unspecified phase) |
0.6095 |
Remote Similarity |
NPD3043 |
Approved |
0.6095 |
Remote Similarity |
NPD1730 |
Discontinued |
0.6095 |
Remote Similarity |
NPD3042 |
Approved |
0.6081 |
Remote Similarity |
NPD9416 |
Phase 3 |
0.6081 |
Remote Similarity |
NPD9417 |
Phase 3 |
0.6078 |
Remote Similarity |
NPD1368 |
Approved |
0.6067 |
Remote Similarity |
NPD3130 |
Discontinued |
0.6054 |
Remote Similarity |
NPD9291 |
Approved |
0.6038 |
Remote Similarity |
NPD515 |
Phase 1 |
0.6011 |
Remote Similarity |
NPD3586 |
Phase 2 |
0.6 |
Remote Similarity |
NPD1063 |
Phase 2 |
0.5988 |
Remote Similarity |
NPD3696 |
Approved |
0.5988 |
Remote Similarity |
NPD3695 |
Approved |
0.5986 |
Remote Similarity |
NPD9626 |
Clinical (unspecified phase) |
0.5968 |
Remote Similarity |
NPD4155 |
Approved |
0.5941 |
Remote Similarity |
NPD9627 |
Approved |
0.5882 |
Remote Similarity |
NPD4240 |
Approved |
0.5882 |
Remote Similarity |
NPD3041 |
Approved |
0.5874 |
Remote Similarity |
NPD2902 |
Phase 2 |
0.5874 |
Remote Similarity |
NPD2903 |
Clinical (unspecified phase) |
0.586 |
Remote Similarity |
NPD3108 |
Clinical (unspecified phase) |
0.5854 |
Remote Similarity |
NPD4495 |
Phase 1 |
0.5829 |
Remote Similarity |
NPD5665 |
Clinical (unspecified phase) |
0.5822 |
Remote Similarity |
NPD8250 |
Phase 2 |
0.5802 |
Remote Similarity |
NPD6381 |
Phase 2 |
0.5787 |
Remote Similarity |
NPD1017 |
Clinical (unspecified phase) |
0.5776 |
Remote Similarity |
NPD4812 |
Phase 1 |
0.5769 |
Remote Similarity |
NPD527 |
Clinical (unspecified phase) |
0.5753 |
Remote Similarity |
NPD3105 |
Discontinued |
0.5731 |
Remote Similarity |
NPD1451 |
Approved |
0.5687 |
Remote Similarity |
NPD5080 |
Phase 2 |
0.5665 |
Remote Similarity |
NPD171 |
Discontinued |
0.564 |
Remote Similarity |
NPD5079 |
Phase 2 |
0.5628 |
Remote Similarity |
NPD6036 |
Suspended |
0.5621 |
Remote Similarity |
NPD9628 |
Approved |
0.5621 |
Remote Similarity |
NPD9133 |
Approved |
0.5612 |
Remote Similarity |
NPD1250 |
Clinical (unspecified phase) |
0.561 |
Remote Similarity |
NPD1356 |
Approved |
0.561 |
Remote Similarity |
NPD1354 |
Approved |
0.561 |
Remote Similarity |
NPD1355 |
Clinical (unspecified phase) |
0.56
|
Remote Similarity |
NPD8837 |
Clinical (unspecified phase) |